Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.

ABSTRACT: As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety of adverse events that may accompany CRS and for recognizing that presentations of CRS may differ among various immunotherapies (e.g., monoclonal antibodies, CAR T cell therapies and T cell engagers, which can include bispecific antibodies and other constructs). The goals of this paper are to ensure accurate and consistent identification of CRS in patients receiving immunotherapies in clinical studies to aid in reporting; enable more precise evaluation of the therapeutic risk-benefit profile and

SUBMITTER: Stewart MD 

PROVIDER: S-EPMC9721456 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature